Cargando…
A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
Pancreatic cancer has one of the highest mortality rates among cancers, and a combination of nab-paclitaxel with gemcitabine remains the cornerstone of first-line therapy. However, major advances are required to achieve improvements in patient outcomes. For this reason, several research groups have...
Autores principales: | Chapa-González, Christian, López, Karina, Lomelí, Kimberly Michelle, Roacho-Pérez, Jorge Alberto, Stevens, Jazmín Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953820/ https://www.ncbi.nlm.nih.gov/pubmed/35330078 http://dx.doi.org/10.3390/life12030327 |
Ejemplares similares
-
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023) -
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
por: Damm, Marko, et al.
Publicado: (2021) -
Real-world comparative effectiveness of nab-paclitaxel plus
gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a
systematic review
por: Chiorean, Elena Gabriela, et al.
Publicado: (2019) -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020) -
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)